本文關鍵詞： 生物制藥 財務角度 成長性 評價　出處：《廣東工業(yè)大學》2014年碩士論文　論文類型：學位論文

【摘要】：生物制藥行業(yè)是我國近十年來重點扶持的高科技行業(yè)。雖然生物制藥行業(yè)在國家政策支持和市場需求增加下迅速發(fā)展起來,但生物制藥行業(yè)在發(fā)展過程中卻出現(xiàn)產(chǎn)品安全問題和自主創(chuàng)新能力低下等問題。同時目前處于轉(zhuǎn)型時期,原材料價格上漲、出口量萎縮和融資渠道縮小所引發(fā)不同程度的財務困境,成了阻礙我國生物制藥行業(yè)穩(wěn)定成長的不利因素。因此,本文的研究目的在于通過找出影響生物制藥公司成長性的因素,基于財務視角,建立能有效反映生物制藥公司成長性的評價指標,并通過因子分析法算出綜合得分,對結果進行客觀的評價和給予相對應提升公司成長性的建議。 本文主要有以下五部分內(nèi)容：第一章是緒論部分,主要說明論文的研究背景、研究意義、研究內(nèi)容和研究方法、主要貢獻。第二章是文獻綜述,主要在對成長性概念界定的基礎上,梳理成長性發(fā)展理論,歸納和評述成長性的影響因素和評價指標。第三章首先歸納和總結生物制藥行業(yè)的特點,然后通過工業(yè)總產(chǎn)值、銷售產(chǎn)值、研發(fā)投入等指標分析目前我國生物制藥行業(yè)的現(xiàn)狀,最后結合兩者情況歸納出影響我國生物制藥行業(yè)成長性的因素。第四章主要從成長質(zhì)量、風險、速度、效率、創(chuàng)新、社會責任、現(xiàn)金流運作七個維度共十八個財務指標建立我國生物制藥公司成長性的評價指標,選取了2010年前已在我國滬深股市上市的89家生物制藥公司,以2010-2012年數(shù)據(jù)為樣本,借助spss16.0統(tǒng)計軟件并采用因子分析法計算樣本公司成長性的各因子得分和綜合得分。第五章根據(jù)得分結果從三方面進行成長性評價：第一,總體上看,生物制藥上市公司整體成長性表現(xiàn)不佳,僅有6.74%的樣本公司成長性表現(xiàn)良好；第二,從地域上看,無論是樣本總量還是成長性綜合得分,東部地區(qū)生物制藥上市公司的成長性比較強；第三,從成長性動力來看,公司的盈利狀況、現(xiàn)金運作情況、對消費者的貢獻程度、技術創(chuàng)新能力、企業(yè)資產(chǎn)運營狀況、發(fā)展速度都會對生物制藥公司成長性的綜合得分有較大的影響。最后針對評價結果以及生物制藥公司發(fā)展狀況,給出提升生物制藥公司成長性的建議：首先要加強公司自身的生產(chǎn)管理,生產(chǎn)出高質(zhì)量高附加值的生物藥品；其次提高產(chǎn)品的銷售能力,加快存貨的周轉(zhuǎn),使得公司在經(jīng)營運作中有較快較多的現(xiàn)金流投入；最后把現(xiàn)金流用到生物制藥公司核心研發(fā)項目中。
[Abstract]:Biopharmaceutical industry is a high-tech industry supported by our country in recent ten years, although the biopharmaceutical industry has developed rapidly under the support of national policy and the increase of market demand. However, in the process of development, the biopharmaceutical industry has problems such as product safety and low independent innovation ability. At the same time, the price of raw materials is rising in the period of transition. The shrinkage of export volume and the narrowing of financing channels lead to different degrees of financial distress, which are the unfavorable factors that hinder the steady growth of the biopharmaceutical industry in China. The purpose of this paper is to find out the factors that affect the growth of biopharmaceutical companies, and based on the financial perspective, to establish an evaluation index that can effectively reflect the growth of biopharmaceutical companies. And through factor analysis to calculate the comprehensive score, the results of objective evaluation and give corresponding recommendations to promote the growth of the company. This article has the following five parts: the first chapter is the introduction part, mainly explains the research background, the research significance, the research content and the research method, the main contribution. The second chapter is the literature review. On the basis of the definition of the concept of growth, this paper combs the theory of growth development, summarizes and comments on the influencing factors and evaluation indicators of growth. Chapter three summarizes and summarizes the characteristics of biopharmaceutical industry. Then through the industrial output value, sales value, R & D input and other indicators to analyze the current status of the biological pharmaceutical industry in China. Finally, combined with the two conditions, the factors that affect the growth of the biopharmaceutical industry in China are summed up. Chapter 4th mainly from growth quality, risk, speed, efficiency, innovation, social responsibility. Cash flow operation seven dimensions a total of 18 financial indicators to establish the growth of Chinese biopharmaceutical companies evaluation indicators, selected from the 2010 in the Shanghai and Shenzhen stock market listed 89 biopharmaceutical companies. Take the data for 2010-2012 as a sample. With the help of spss16.0 statistical software and factor analysis method to calculate the sample company growth factor score and comprehensive score. Chapter 5th according to the score results from three aspects of growth evaluation: first. On the whole, the overall growth performance of biopharmaceutical listed companies is not good, only 6.74% of the sample companies have good growth performance; Second, from the geographical point of view, whether the sample total or growth comprehensive score, the eastern region of the biopharmaceutical listed companies have a strong growth; Third, from the perspective of growth dynamics, the company's profitability, cash operation, the degree of contribution to consumers, technological innovation ability, enterprise assets operation. The speed of development will have a greater impact on the growth of biopharmaceutical companies. Finally, the evaluation results and the development of biopharmaceutical companies. Some suggestions are given to promote the growth of biopharmaceutical companies: firstly, we should strengthen the company's own production management to produce high quality and high added value biological drugs; Secondly, improve the sales ability of products, speed up the turnover of inventory, so that the company has a faster cash flow input in the operation; Finally, the cash flow is used in the core R & D projects of biopharmaceutical companies.
【學位授予單位】：廣東工業(yè)大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：F426.72;F275

【引證文獻】

相關期刊論文 前1條

1 李青;;資產(chǎn)結構對企業(yè)績效的影響研究[J];全國商情;2016年32期

相關碩士學位論文 前1條

1 魏彤昕;生物制藥企業(yè)價值評估中的收益法探究[D];首都經(jīng)濟貿(mào)易大學;2016年

，

本文編號：1475304